Cybin Begins Study Using Kernel Flow Headsets To Measure Ketamine's Effects On The Brain

The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway,  announced Cybin Inc. CYBN, which is sponsoring the research that will make heavy use of Kernel Flow, a quantitative neuroimaging technology.

Without the need for a more expensive and oversized piece of equipment, Kernal Flow is a wearable headset that measures brain activity by recording local changes in blood oxygenation. Study participants will wear the headset while being administered either a low dose of ketamine or a placebo. After that, they will report their experience using structured questionnaires and validated assessments during in-study visits and at follow-up. The four-week study will also evaluate brain activity before and after administering the agents.

The FDA gave investigational new drug (IND) authorization for the study in October 2021.

“To this point, studies have had to rely on subjective patient reporting”, explained Doug Drysdale, Cybin’s CEO. “This is the first time any company has had the ability to collect and quantify longitudinal brain activity before, during, and after a psychedelic experience.”

Photo: Courtesy of Louis Reed on Unsplash


Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksPsychedelicsMarketsCybinKernelKetamine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Top Cannabis Event In New Jersey

Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!